Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Roberta S. Azevedo, Hagop Kantarjian, Jayastu Senapati, Ian Bouligny, Alexandre Bazinet, Wei-Ying Jen, Amin Alousi, Uday Popat, Elizabeth Shpall, Naveen Pemmaraju, Nitin Jain, Eitan Kugler, Cody Belgarde, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2025-1630

Published: 2025

Journal Articles

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Eitan Kugler, Jayastu Senapati, Sanam Loghavi, Farhad Ravandi, Alexandre Bazinet, Alex Bataller, Courtney DiNardo, Danielle Hammond, Kelly Chien, Wei-Ying Jen, Guillermo Montalban-Bravo, Koji Sasaki, Gautam Borthakur, Hagop Kantarjian, Guillermo Garcia-Manero, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2025-3206

Published: 2025

Journal Articles

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Gabriel Aleixo, Heejin Cheon, Jiayin Zheng, Stephanie Soewito, Jimmy Lee, Neha Kalakuntla, Wei-Ying Jen, Sumasri Kotha, Alex Rupsee, Mia Djulbegovic, Jairo Matthews, Tapan Kadia, Timothy Olson, Taha Bat, Courtney DiNardo, Daria Babushok

Blood (2025) 146 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2025-1418

Published: 2025

Journal Articles

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Michelle Nwachukwu, Wei-Ying Jen, Jeremy Ramdial, Caitlin Rausch, Roberta Santos Azevedo, Gautam Borthakur, Courtney DiNardo, Naval Daver, Betul Oran, Richard Champlin, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 6975.

https://doi.org/10.1182/blood-2025-6975

Published: 2025

Journal Articles

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2025-4634

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Journal Articles

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2025-5167

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Blood (2025) 146 (Supplement 1): 997.

https://doi.org/10.1182/blood-2025-997

Published: 2025

Journal Articles

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Blood (2025) 146 (Supplement 1): 47.

https://doi.org/10.1182/blood-2025-47

Published: 2025

Journal Articles

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Vanthana Bharathi, Alexandre Bazinet, Alex Bataller, Naval Daver, Courtney DiNardo, Hussein Abbas, Ian Bouligny, Gautam Borthakur, Fadi Haddad, Naveen Pemmaraju, Steven Kornblau, Wei-Ying Jen, Nicholas Short, Andres Quesada, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3405.

https://doi.org/10.1182/blood-2025-3405

Published: 2025

Journal Articles

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Sankalp Arora, Jayastu Senapati, Nicholas Short, Musa Yilmaz, Sanam Loghavi, Tapan Kadia, Courtney DiNardo, Gautam Borthakur, Joseph Jabbour, Hannah Goulart, Ghayas Issa, Naveen Pemmaraju, Wei-Ying Jen, Hussein Abbas, Michael Andreeff, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 3397.

https://doi.org/10.1182/blood-2025-3397

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

William D. Marrero, Mina Abdelmalek, Farah Al Haj, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sanam Loghavi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Jayastu Senapati, Wei-Ying Jen, Naveen Pemmaraju, Fnu Amritpal Singh, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Naval Daver

Blood (2025) 146 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2025-5179

Published: 2025

Journal Articles

Luspatercept response predictors in lower-risk myelodysplastic syndrome

Vanthana Bharathi, Ian Bouligny, Emmanuel Almanza, Alex Bataller, Alexandre Bazinet, Wei-Ying Jen, Niranjan Khaire, Koji Sasaki, Danielle Hammond, Courtney DiNardo, Gautam Borthakur, Tapan Kadia, Naval Daver, Ghayas Issa, Musa Yilmaz, Kelly Chien, Guillermo Montalban-Bravo, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 5648.

https://doi.org/10.1182/blood-2025-5648

Published: 2025

Journal Articles

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 5647.

https://doi.org/10.1182/blood-2025-5647

Published: 2025

Journal Articles

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Michelle Nwachukwu, Farhad Ravandi, Sanam Loghavi, Gautam Borthakur, Tapan Kadia, Courtney DiNardo, Nicholas Short, Elias Jabbour, Guillermo Montalban-Bravo, Alexandre Bazinet, Alex Bataller, Kelly Chien, Danielle Hammond, Mahesh Swaminathan, Wei-Ying Jen, Ian Bouligny, Naval Daver, Guillermo Garcia-Manero, Koji Sasaki

Blood (2025) 146 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2025-1620

Published: 2025

Journal Articles

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Blood (2025) 146 (Supplement 1): 6950.

https://doi.org/10.1182/blood-2025-6950

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Characteristics and outcomes of CEBPA bZIP in-frame mutations in de novo and treated secondary acute myeloid leukemia

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome

Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML

Clinicopathological characteristics and survival outcomes in adults with acute megakaryoblastic leukemia

Treatment intensity may alter the prognostic impact of baseline co-mutations in newly diagnosed FLT3-ITD AML treated with FLT3 inhibitor-based therapy

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Acute Myeloid Leukemia with deletion 12p: An adverse-risk disease

Luspatercept response predictors in lower-risk myelodysplastic syndrome

A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Clinical characteristics, demographics, and survival outcomes in newly diagnosed CUX1-mutated Acute Myeloid Leukemia

Cardiac safety of revumenib in children with HOX-driven leukemia: A single-institution cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only